Non-squamous

First-line treatment of nonsquamous non–small cell lung cancer (NSCLC) has undergone a paradigm shift to platinum combination therapy together with immune checkpoint inhibitors (ICIs). However, phase III studies of combinations of cytotoxic chemotherapy and ICIs have included only patients with maintained organ function, not those with renal impairment.

5p vialfrednobel 23-12-2023 9 3   Download

The addition of bevacizumab to cytotoxic agents prolongs survival in patients with nonsquamous non-small cell lung cancer (NSCLC). To date, there is no evidence to suggest that treatment with a cytotoxic agent plus bevacizumab is more effective than a cytotoxic agent alone for nonsquamous NSCLC in elderly patients.

7p vinaypyidaw2711 26-08-2020 20 2   Download

Targeted treatment with Epidermal Growth Factor Receptor (EGFR) tyrosine kinase inhibitors (TKIs) is superior to systemic chemotherapy in non-small cell lung cancer (NSCLC) patients with EGFR gene mutations.

12p vidhaka2711 31-07-2020 14 1   Download

In recent years, systemic chemotherapy and molecular targeted therapy have become standard firstline treatments for locally advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC).

7p vidhaka2711 31-07-2020 8 1   Download

We evaluated the safety and efficacy of induction chemotherapy with bevacizumab followed by maintenance chemotherapy with bevacizumab for advanced non-small cell lung cancer (NSCLC) in this multicenter phase II study.

7p viputrajaya2711 22-06-2020 14 0   Download